<PAGE> 1
===============================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------
FORM 10-QSB
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended March 31, 1997
or
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934
For the transition period from to
-------------
Commission file number 0-27914
RIBOZYME PHARMACEUTICALS, INC.
(Exact Name of Small Business Issuer as Specified in Its Charter)
-------------
Delaware 34-1697351
(State of incorporation) (I.R.S. Employer Identification No.)
2950 Wilderness Place
Boulder, Colorado 80301
(Address of principal executive offices)
Registrant's telephone number: (303) 449-6500
-------------
Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes X No
--- ---
The number of shares of the registrant's common stock, par value $0.01 per
share, outstanding as of May 6, 1997 was 6,981,053.
===============================================================================
<PAGE> 2
RIBOZYME PHARMACEUTICALS, INC.
INDEX TO FORM 10-QSB
PART 1 - FINANCIAL INFORMATION PAGE
----
Item 1. Financial Statements (Unaudited)
Condensed Balance Sheet - March 31, 1997.......................... 3
Condensed Statements of Operations - Three Months Ended
March 31, 1997 and 1996........................................... 4
Condensed Statements of Cash Flows - Three Months Ended
March 31, 1997 and 1996........................................... 5
Notes to Condensed Financial Statements........................... 6
Item 2. Management's Discussion and Analysis or Plan of Operation......... 7
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K.................................. 9
SIGNATURES................................................................ 10
Exhibit Index............................................................. 11
2
<PAGE> 3
PART I. FINANCIAL INFORMATION
ITEM I. FINANCIAL STATEMENTS
RIBOZYME PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEET
(Unaudited)
<TABLE>
<CAPTION>
March 31,
ASSETS 1997
------------
Current assets
<S> <C>
Cash and cash equivalents $ 9,672,868
Securities available-for-sale 4,538,884
Restricted cash 193,263
Accounts receivable 38,541
Notes receivable-related parties 131,591
Prepaid expenses and other 138,040
------------
Total current assets 14,713,187
Equipment and leasehold improvements at cost, net
of accumulated depreciation and amortization 4,554,730
Restricted cash 30,096
Notes receivable-related parties 84,932
Deferred patents, net 2,071,562
Other assets, net 422,036
------------
Total assets $ 21,876,543
============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable, trade $ 629,524
Accrued liabilities 112,288
Current portion of long-term debt and capital
lease obligations 1,529,196
------------
Total current liabilities 2,271,008
Long-term debt and capital lease obligations 2,232,371
Deferred gain 4,029
Stockholders' equity
Common stock 69,640
Additional paid-in capital 67,900,517
Deferred compensation
(202,480)
Accumulated deficit (50,398,542)
------------
Total stockholders' equity 17,369,135
------------
Total liabilities and stockholders' equity $ 21,876,543
============
</TABLE>
See notes to condensed financial statements
3
<PAGE> 4
RIBOZYME PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
----------------------------
1997 1996
----------- -----------
Revenues:
<S> <C> <C>
Collaborative agreements $ 394,000 $ 559,122
Grant and other income 1,486 800
Interest income 205,495 59,048
----------- -----------
Total revenues 600,981 618,970
----------- -----------
Expenses:
Research and development 2,982,318 3,029,104
General and administrative 389,590 470,598
Interest expense 244,785 221,694
----------- -----------
Total expenses 3,616,693 3,721,396
----------- -----------
Net loss $(3,015,712) $(3,102,426)
=========== ===========
Net loss per share $ (0.43) $ (0.92)
=========== ===========
Shares used in computing net loss per share 6,957,256 3,372,366
=========== ===========
</TABLE>
See notes to condensed financial statements.
4
<PAGE> 5
RIBOZYME PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
---------------------------------
1997 1996
---------------- ----------------
<S> <C> <C>
OPERATING ACTIVITIES
Net loss $ (3,015,712) $ (3,102,426)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 413,063 445,132
Compensation for forgiveness of notes
receivable-related parties 62,466 62,466
Loss on sale of securities - 8,577
Changes in operating assets and liabilities:
Accounts receivable 35,481 12,175
Prepaid expenses and other 75,679 (301,130)
Other assets (8,901) 162
Accounts payable 76,619 112,606
Accrued liabilities (104,329) (20,246)
Deferred gain (1,486) (9,388)
------------- ------------
Net cash used in operating activities (2,467,120) (2,792,072)
INVESTING ACTIVITIES
Additions to property, plant and equipment, net (546,424) (714,594)
Additions to patents and other intangible assets, net (71,526) (89,652)
Net sales of securities available-for-sale 218 2,498,552
Transfer of restricted cash 72,043 -
Loan repayments-related parties 750 -
Loan advancements-related parties - (75,000)
------------- ------------
Net cash (used in) provided by investing activities (544,939) 1,619,306
FINANCING ACTIVITIES
Net proceeds from sale of shares of common stock 27,394 36,189
Proceeds from issuance of long-term debt - 411,238
Principal payments on long-term debt and capital lease obligations (393,145) (480,653)
------------- ------------
Net cash used in financing activities (365,751) (33,226)
Net decrease in cash and cash equivalents (3,377,810) (1,205,992)
Cash and cash equivalents at beginning of period 13,050,678 2,913,009
------------- ------------
Cash and cash equivalents at end of period $ 9,672,868 $ 1,707,017
============= ============
</TABLE>
See notes to condensed financial statements.
5
<PAGE> 6
RIBOZYME PHARMACEUTICALS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
March 31, 1997
(Unaudited)
Note 1: Basis of Presentation
The accompanying unaudited condensed financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-QSB and Item
310(b) of Regulation S-B. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of management, all
adjustments (consisting of normal recurring accruals) considered necessary of a
fair presentation have been included. Operating results for the three-month
period ending March 31, 1997 are not necessarily indicative of the results that
may be expected for the year ended December 31, 1997. For further information,
refer to the financial statements and footnotes thereto included in the
Company's annual report on Form 10-KSB for the year ended December 31, 1996.
Note 2: Net loss per share
Pursuant to the Securities and Exchange Commission Staff Accounting
Bulletins, common and common equivalent shares issued during the 12-month
period prior to the Company's initial public offering on April 11, 1996, at
prices below the public offer price have been included in the calculation as if
they were outstanding for all periods presented (using the treasury stock
method and the initial public offering price of $10.00 per share). Furthermore,
pursuant to Staff policy, common equivalent shares from convertible preferred
shares that converted upon completion of the Company's initial public offering
are included (using the if-converted method) even when antidilutive.
Had net loss per share been presented on the historical basis, average
shares outstanding would have equaled 1,040,529 and net loss per share would
have been $2.98 for the three months ended March 31, 1996.
In February 1997, the Financial Accounting Standards Board issued
Statement No. 128, Earnings per Share, which is required to be adopted on
December 31, 1997. At that time, the Company will be required to change the
method currently used to compute earnings per share and to restate all prior
periods. Under the new requirements for calculating primary earnings per share,
the dilutive effect of stock options will be excluded. The impact of Statement
No. 128 on these quarters is not expected to be material.
6
<PAGE> 7
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
OVERVIEW
Ribozyme Pharmaceuticals, Inc. ("RPI") is a public company that was
founded to capitalize on the broad potential of ribozymes for use as human
therapeutics and in other areas, including the identification of gene function
and therapeutic target validation. Ribozymes are a form of RNA that have the
ability to selectively inhibit protein production. RPI has entered into
collaborations with Chiron Corporation and the Parke-Davis Division of the
Warner Lambert Company to develop ribozyme products for specific therapeutic
targets in human health, with Schering AG plus a second collaboration with
Chiron in the gene function/target validation area, with Pharmacia Biotech AB on
the production-scale synthesis of RNA and chimeric oligonucleotides, with ALZA
Corporation on ribozyme delivery, with Protogene Laboratories to develop
automated machines for high throughput non-DNA nucleic acid synthesis, and with
IntelliGene Corporation for development of ribozyme-based diagnostics.
The Company has incurred losses since inception and, as of March 31,
1997, had an accumulated deficit of $50.4 million. The Company anticipates
incurring additional losses over at least the next several years as it expands
its research and development programs, including pre-clinical studies and
clinical trials. Such expansion will result in increases in research and
development, and general and administrative expenses.
RESULTS OF OPERATIONS
Three Months Ended March 31, 1997 and 1996
Collaborative agreement revenue decreased 30% to $394,000 for the
three month period ended March 31, 1997, from $559,000 for the corresponding
period in 1996. Collaborative agreement and contract revenue fluctuations are
generally the result of changes in the number of funded research projects as
well as the timing and performance of contract milestones. The decrease in 1997
from the corresponding period in 1996 is primarily the result of decreasing
specified one-time payments from Pharmacia Biotech in a collaboration on the
development of improved synthesis and purification methods for the preparation
of modified amidites and chimeric oligonucleotides, as well as payments
received during the first quarter in 1996 for collaborations which have since
terminated.
Interest income increased to $205,000 for the three months ended March
31, 1997 compared to $59,000 for the corresponding period in 1996. The increase
is due to higher average balances in cash and cash equivalents and marketable
securities as a result of the Company's initial public offering completed in
April 1996.
Research and development expenses decreased 2% to $2.9 million for the
three months ended March 31, 1997, compared to $3.0 million for the
corresponding period in 1996. The slight decrease is a timing variance in
outside contract service expenditures. Other expenses in research and
development have increased slightly in the three month period ended March 31,
1997, compared to the corresponding period in 1996. The Company expects overall
increases in research and development expenses as it expands its research and
development programs, including pre-clinical studies and clinical trials.
General and administrative expenses decreased 17% to $390,000 for the
three months ended March 31, 1997, compared to $471,000 for the corresponding
period in 1996. The decrease in general
7
<PAGE> 8
and administrative expenses is primarily due to staffing changes of management
and administrative personnel and a corresponding decrease in travel, supplies
and other expenses related to personnel. The Company expects increases in
general and administrative expenses due to the hiring of management and
administrative personnel and the incurring of legal and other professional fees
in connection with the overall scale-up of the Company's operations and
business development efforts.
Interest expense increased 10% to $245,000 for the period ended March
31, 1997 compared to $222,000 for the period ended March 31, 1996. The increase
is attributable to increased borrowings on long-term debt during 1996 which
were used to fund laboratory and office equipment purchases.
LIQUIDITY AND CAPITAL RESOURCES
The Company's cash, cash equivalents and securities available-for-sale
were $14.2 million at March 31, 1997, compared with $17.6 million at December
31, 1996. The $3.4 million decrease in cash, cash equivalents and securities
available-for-sale was primarily the result of the following:
<TABLE>
<S> <C>
Net cash used in operating activities $(2,467,000)
Investment in property, plant and equipment (546,000)
Additions to patents (72,000)
Transfer of restricted cash 72,000
Payments under loan facilities and capital lease obligations (453,000)
Net proceeds from sale of stock 27,000
Other, net 39,000
-----------
$(3,400,000)
===========
</TABLE>
The Company invests its cash, cash equivalents and securities
available-for-sale in interest-bearing high quality investment grade securities.
Total additions for equipment for the three months ended March 31,
1997, was $546,000. As of March 31, 1997, the Company had approximately $838,000
available for additional equipment purchases under a loan agreement with a
commercial bank. The loan commitment terminates on June 30, 1997.
The Company estimates that its existing capital resources, together
with facility and equipment financing and expected revenues from its
collaborative agreements, will be sufficient to fund its current and planned
operations at least until late 1998. There can be no assurance, however, that
changes in the Company's research and development plans or other changes
affecting the Company's operating expenses will not result in the expenditure of
such resources before such time and, in any event, the Company will need to
raise substantial additional capital to fund its operations in future periods.
Such additional capital may be raised through public or private financing, as
well as collaborative relationships, borrowing and other available sources.
This Form 10-QSB contains forward-looking statements that involve
risks and uncertainties, and actual events or results may differ materially.
These risk factors include actions by the U.S. Food and Drug Administration,
technological advances, ability to obtain rights to technology, ability to
obtain and enforce patents, ability to commercialize and manufacture products
and general economic conditions. These and additional risk factors are
identified in our annual report to the Securities and Exchange Commission filed
on forms 10-KSB and in other SEC filings.
8
<PAGE> 9
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
3(i) Amended and Restated Certificate of Incorporation*
3(ii) Restated Bylaws*
11 Statement re: Computation of net loss and proforma net loss
per share.
27 Financial Data Schedule
99 Press release dated April 14, 1997
(b) Reports on Form 8-K
The Company did not file any reports on Form 8-K during the quarter
for which this report on Form 10-QSB is filed.
- ------
* Incorporated by reference from the Company's Registration Statement on
Form SB-2, file no. 333-1908-D.
9
<PAGE> 10
SIGNATURES
In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
RIBOZYME PHARMACEUTICALS, INC.
Dated: May 15, 1997 By: /s/ RALPH E. CHRISTOFFERSEN
------------ --------------------------------
Ralph E. Christoffersen
President and Chief
Executive Officer
Dated: May 15, 1997 By: /s/ LAWRENCE E. BULLOCK
------------ --------------------------------
Lawrence E. Bullock
Vice President and Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)
<PAGE> 11
EXHIBIT INDEX
Exhibit Exhibit
No. Description
------- -----------
3(i) Amended and Restated Certificate of Incorporation*
3(ii) Restated Bylaws*
11 Statement re: Computation of net loss and pro forma net
loss per share.
27 Financial Data Schedule
99 Press release dated April 14, 1997.
- -----
* Incorporated by reference from the Company's Registration Statement on Form
SB-2, File No. 333-1908-D.
<PAGE> 1
EXHIBIT 11.0
RIBOZYME PHARMACEUTICALS, INC.
COMPUTATION OF PRO FORMA NET LOSS PER SHARE
<TABLE>
<CAPTION>
Quarter Quarter
ending ending
03/31/97 03/31/96
------------ ------------
<S> <C> <C>
Weighted average common shares
outstanding 6,957,256 1,040,529
Net effect of dilutive common stock
options and warrants pursuant to
Staff Accounting Bulletin No. 83 0
99,877
Assumed conversion of preferred stock
from original date of issuance,
pursuant to staff policy 0 2,231,960
----------- -----------
Total 6,957,256 3,372,366
Net loss $(3,015,712) $(3,102,426)
=========== ===========
Pro forma net loss per share $ (0.43) $ (0.92)
=========== ===========
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF RIBOZYME PHARMACEUTICALS, INC. FOR THE THREE MONTHS
ENDED MARCH 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 9,672,868
<SECURITIES> 4,538,884
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 14,675,721
<PP&E> 8,596,574
<DEPRECIATION> 4,041,844
<TOTAL-ASSETS> 21,876,543
<CURRENT-LIABILITIES> 2,271,008
<BONDS> 0
0
0
<COMMON> 69,640
<OTHER-SE> 17,299,495
<TOTAL-LIABILITY-AND-EQUITY> 21,876,543
<SALES> 0
<TOTAL-REVENUES> 600,981
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 2,982,318
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 244,785
<INCOME-PRETAX> (3,015,712)
<INCOME-TAX> 0
<INCOME-CONTINUING> (3,015,712)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,015,712)
<EPS-PRIMARY> (0.43)
<EPS-DILUTED> 0
</TABLE>
<PAGE> 1
EXHIBIT 99
Contacts:
Ribozyme Pharmaceuticals, Inc. Noonan/Russo Communications, Inc.
Ralph E. Christoffersen, Ph.D. (212) 696-4455
CEO and President Anthony J. Russo, Ph.D., ext. 202 (media)
(303) 449 - 6500 Amy Martini, ext. 255 (investors)
RIBOZYME SIGNS MAJOR TARGET VALIDATION AND THERAPEUTIC DEVELOPMENT
DEAL WITH SCHERING AG, GERMANY
Boulder, Colorado; April 14, 1997 - Ribozyme Pharmaceuticals, Inc.
(RPI) (NASDAQ:RZYM) today announced that they have signed a major research
collaboration with Schering AG, Germany, focusing on the use of ribozymes for
therapeutic target validation, as well as the development of ribozymes as
therapeutic agents.
The collaboration will utilize the special selectivity of ribozymes to validate
new molecular therapeutic targets, and to discover new therapeutic agents based
on those targets. RPI will provide its expertise in ribozyme design, synthesis
and delivery, and Berlex Laboratories, Inc., a U.S. subsidiary of Schering AG,
Germany, will provide candidate targets, cell culture screens, animal models
and development and commercialization expertise to the collaboration. It is
anticipated that hundreds of potential targets will be examined over a five
year period, and Berlex will have options to commercialize products from
validated targets.
Schering AG, Germany will make an equity investment of up to $5 million over
the next year and will separately provide loans of up to $2 million for each of
the next five years. These loans are convertible into equity at the option of
Schering AG, Germany under certain circumstances. In addition, Schering AG,
Germany will make research payments of $2 million a year for the next five
years and RPI may earn success fees and product development milestones, and
will manufacture synthetic ribozyme products and receive royalties on both
ribozyme and non-ribozyme products. All such payments are subject to certain
restrictions, including receipt of certain third party consents and the
termination of the research collaboration at Schering AG, Germany's option upon
one year's notice. Under certain circumstances, total payments to RPI during
the collaboration and prior to product sales could exceed $60 million over the
term of the collaboration.
"This is RPI's second partnership in the area of target validation, and is
consistent with RPI's strategy to offer ribozyme target validation screening
capabilities to multiple partners," said Dr. Ralph Christoffersen, President
and CEO of RPI. "We believe that our ribozyme target validation technology goes
beyond determination of biological function of genes, and forms a natural and
significant extension of genome sequencing efforts. Target validation and the
development of ribozyme-based therapeutics against these targets are an
important part of RPI's strategy for ribozyme commercialization, and it is a
real pleasure for RPI to initiate this collaboration with Schering AG, Germany,
who brings significant
<PAGE> 2
expertise, reagents and resources to the collaboration. We look forward to the
validation of many new therapeutic targets and creation of new products."
RPI is a public company that was founded to capitalize on the broad potential
of ribozymes for use as human therapeutics and in other areas, including the
identification of gene function and therapeutic target validation. Ribozymes
are a form of RNA that have the ability to selectively inhibit protein
production. RPI has also entered into collaborations with Chiron Corporation
and the Parke-Davis Division of the Warner Lambert Company to develop ribozyme
products for specific therapeutic targets in human health, a second
collaboration with Chiron in the gene function/target validation area, with
DowElanco for certain agricultural applications, with Pharmacia Biotech AB on
the production-scale synthesis of RNA and chimeric oligonucleotides, with Alza
Corporation on ribozyme delivery, with Protogene laboratories to develop
automated machines for high throughput non-DNA nucleic acid synthesis, and with
IntelliGene Corporation for development of ribozyme-based diagnostics.
###
Editor's Note: This release is also available on the Internet at
http://www.noonanrusso.com
